Date / Time	PHYSICIAN'S ORDERS – MUST BE SIGNED BY A PHYSICIAN

Order for Drotrecogin Alfa Activated (Xigris®) Page 1 of 2

PHARMACY IS NOT PERMITTED TO DISPENSE THIS MEDICATION UNTIL THIS FORM IS COMPLETED

Patient must be in an intensive care unit (ICU, CCU, and CSU) to receive drotrecogin

Patient must meet at least 3 of the following criteria (check all that apply):

- ☐ Temperature ≥38° C or ≤36° C (rectal, central catheter or tympanic measurement). If axillary temperature is used, add 0.5°C to the measured value.
- ☐ Heart rate ≥90 beats/min in the absence of a known medical condition that would prevent tachycardia (e.g., heart block, beta-blockers). In the presence of a known medical condition that would prevent tachycardia, the patient only has to meet 2 of the other criteria for infection.
- ☐ Respiratory rate ≥20 breaths/min or PaCO2 ≤32 mmHg or mechanical ventilation for an acute process that is not related to a neuromuscular disease or the need for general anesthesia.
- ☐ WBC > 12,000/mm^3, < 4000/mm^3, or > 10% immature neutrophils (bands)

Patients must present with at least 2 of the following criteria (check all that apply):

- ☐ Cardiovascular organ dysfunction
  - An arterial systolic blood pressure of < 90 mmHg or a mean arterial pressure (MAP) = 70 mmHg for at least 1 hour despite adequate fluid resuscitation
  - Adequate intravascular volume status and the need for vasopressors to maintain systolic blood pressure (SBP) > 90 mmHg or MAP > 70 mmHg
- ☐ Renal dysfunction
  - Urine output < 0.5 ml/kg/hr for 1 hour despite adequate fluid resuscitation
- ☐ Respiratory dysfunction
  - Ratio of PaO2/FiO2 ≤ 250 in the presence of other dysfunctional organs or systems (if the lung is the only dysfunctional organ, the ratio of PaO2/FiO2 must be ≤ 200)
- ☐ Hematologic dysfunction
  - Platelet count of < 80,000/mm^3 or decreased by 50% in the past 3 days
- ☐ Metabolic acidosis
  - pH ≤ 7.30 or base deficit ≥ 5.0 mEq/L with a plasma lactate level >1.5 times normal
- ☐ Other evidence of organ dysfunction

Contraindications: Xigris® increases the risk of bleeding. Xigris® is contraindicated in patients with the following clinical conditions. None of the following conditions are present:

- Active internal bleeding
- Recent (within 3 months) hemorrhagic stroke
- Recent (within 2 months) intracranial or intraspinal surgery, or severe head trauma requiring hospitalization
- Trauma patients with increased risk of life-threatening bleeding
- Presence of an epidural catheter
- Intracranial neoplasm or mass lesion or evidence of cerebral herniation
- Patients with known hypersensitivity to drotrecogin alfa or any component of the product
- Patient weight >135 kilograms
- Patient <18 years old

Physician's Signature **Date**

Authorization is given to dispense a generic equivalent unless the drug is circled (according to formulary policy)

Patient Information

Drotrecogin Alfa Activated (Xigris®)
University Hospital

UC4027 3/02

Date / Time	PHYSICIAN'S ORDERS – MUST BE SIGNED BY A PHYSICIAN

Order for Drotrecogin Alfa Activated (Xigris®) – Page 2 of 2

Warnings: Bleeding is the most common serious adverse effect associated with Xigris® therapy. For patients with severe sepsis who have ONE or more of the following conditions, the increased risk of bleeding should be carefully considered when deciding whether to use Xigris® therapy.

- Concurrent therapeutic heparin (≥ 15 units/kg/hr)
- Platelet count <30,000 x 10^{6}/L even if the platelet count is increased after transfusions
- Prothrombin time – INR >3.0
- Recent (within 6 weeks) gastrointestinal bleeding
- Recent administration (within 3 days) of thrombolytic therapy
- Recent administration (within 7 days) of oral anticoagulants or glycoprotein IIb/IIIa inhibitors
- Recent administration (within 7 days) of aspirin >650 mg per day or other platelet inhibitors
- Recent (within 3 months) ischemic stroke
- Known bleeding diathesis
- Chronic severe hepatic disease
- Chronic renal failure requiring hemodialysis or peritoneal dialysis

Guidelines for Stopping the Infusion if an Invasive Procedure is Needed

Procedure	Time Pre-Procedure to Stop Xigris® Infusion	Time Post-Procedure to Restart Xigris® Infusion
Surgical Procedure*	2 hours prior to procedure	12 hours after procedure
Lumbar puncture Tracheostomy Chest tube insertion Thoracic drainage	2 hours prior to procedure	1 hour after procedure**
Sinus puncture	2 hours prior to procedure	Immediately after procedure**
Arterial catheter Central venous catheter Re-intubation (tube change)	1 hour prior to procedure	Immediately after procedure**

*A significant surgical procedure that requires the use of an operating room, anesthesia, etc.
**If no signs and symptoms of bleeding are present and a minimal risk of bleeding complication is expected

Dose: 24 mcg/kg/hr for no longer than 96 hours. Pharmacy to calculate dose and dispense drotrecogin alfa for 96 hours unless prescribing physician discontinues order before then.

Patient's weight (please fill out):_____**kg lb (circle one)**

References:
1. Bernard GR et al. Efficacy and safety of recombinant human activated protein C for severe sepsis *N Engl J Med.* 2001;344:699-709.
2. Xigris product information. Eli Lilly and Company, November 2001.

Physician's Signature_____ Pager#:_____ Date:_____

Prescribing physician must be one of the following (Please check one):

☐ Pulmonologist
☐ Infectious Disease
☐ Critical Care Intensivist

Authorization is given to dispense a generic equivalent unless the drug is circled (according to formulary policy)

Patient Information

Drotrecogin Alfa Activated (Xigris®)
University Hospital